Table S3. Shared miRNAs binding sites prediction in human HER2 and HER4 3âUTR. (XLSX 12 kb
Table S2. TCGA tissue microRNAs differentially expressed for DPBC versus normal tissue (fold change ...
Table S3. Univariate and multivariate Cox proportional hazards regression model analysis of PFS in b...
Table S2. Downregulated mRNAs after miR-1287 overexpression in the cell line SUM159. This list shows...
Table S4. miRNAs binding sites prediction in human HER2 and HER3 3âUTR. (XLSX 26 kb
Figure S4. Correlation between miR-125a/b and EGFR family proteins in HER2 positive breast cancer pa...
Figure S1. Effect of trastuzumab on miR-125a/b levels. Real-time PCR analysis of miR-125a and miR-12...
Figure S5. Reciprocal ceRNA activity between HER2 and HER3 3âUTR. HER2 3âUTR-luciferase reporter...
Table S2. Gene-set enrichment analysis in T47D cells transfected with HER2â3âUTR or control vect...
Table S1. Gene fold changes in T47D cells transfected with HER2â3âUTR or control vector. (XLSX 8...
Figure S2. Effect of trastuzumab on HER2 and HER3 levels. FACS analysis of HER2 and HER3 levels in A...
Table S3. TCGA tissue microRNAs differentially expressed for TNBC versus DPBC cancers (fold change ≤...
Figure S6. Effect of trastuzumab on HER2 protein levels. Western blot analysis of HER2 levels in AU5...
Figure S3. Combinatory treatment with HER3 siRNA and trastuzumab is useful for overcoming trastuzuma...
Table S1. TCGA tissue microRNAs differentially expressed for TNBC versus normal tissue (fold change ...
Nine differentially expressed miRNAs from miRNA microarray assay in TNBC and adjacent normal tissues...
Table S2. TCGA tissue microRNAs differentially expressed for DPBC versus normal tissue (fold change ...
Table S3. Univariate and multivariate Cox proportional hazards regression model analysis of PFS in b...
Table S2. Downregulated mRNAs after miR-1287 overexpression in the cell line SUM159. This list shows...
Table S4. miRNAs binding sites prediction in human HER2 and HER3 3âUTR. (XLSX 26 kb
Figure S4. Correlation between miR-125a/b and EGFR family proteins in HER2 positive breast cancer pa...
Figure S1. Effect of trastuzumab on miR-125a/b levels. Real-time PCR analysis of miR-125a and miR-12...
Figure S5. Reciprocal ceRNA activity between HER2 and HER3 3âUTR. HER2 3âUTR-luciferase reporter...
Table S2. Gene-set enrichment analysis in T47D cells transfected with HER2â3âUTR or control vect...
Table S1. Gene fold changes in T47D cells transfected with HER2â3âUTR or control vector. (XLSX 8...
Figure S2. Effect of trastuzumab on HER2 and HER3 levels. FACS analysis of HER2 and HER3 levels in A...
Table S3. TCGA tissue microRNAs differentially expressed for TNBC versus DPBC cancers (fold change ≤...
Figure S6. Effect of trastuzumab on HER2 protein levels. Western blot analysis of HER2 levels in AU5...
Figure S3. Combinatory treatment with HER3 siRNA and trastuzumab is useful for overcoming trastuzuma...
Table S1. TCGA tissue microRNAs differentially expressed for TNBC versus normal tissue (fold change ...
Nine differentially expressed miRNAs from miRNA microarray assay in TNBC and adjacent normal tissues...
Table S2. TCGA tissue microRNAs differentially expressed for DPBC versus normal tissue (fold change ...
Table S3. Univariate and multivariate Cox proportional hazards regression model analysis of PFS in b...
Table S2. Downregulated mRNAs after miR-1287 overexpression in the cell line SUM159. This list shows...
DOI
Add to ORKG